Anti-reflux mucosal ablation for refractory gastroesophageal reflux disease after Roux-en-Y gastric bypass

CC BY 4.0 · Endoscopy 2024; 56(S 01): E37-E38
DOI: 10.1055/a-2223-0499

E-Videos

Authors

Fares Ayoub

¹Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, United States (Ringgold ID: RIN3989)
Kalpesh K. Patel

¹Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, United States (Ringgold ID: RIN3989)

References
1 Frezza EE, Ikramuddin S, Gourash W. et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc 2002; 16: 1027-1031
2 Siilin H, Wanders A, Gustavsson S. et al. The proximal gastric pouch invariably contains acid-producing parietal cells in Roux-en-Y gastric bypass. Obes Surg 2005; 15: 771-777
3 Nguyen NT, Thosani NC, Canto MI. et al. The American Foregut Society white paper on the endoscopic classification of esophagogastric junction integrity. Foregut 2022; 2: 339-348
4 Motola D, Zeini IM, Moon RC. et al. Anti-reflux procedures after Roux-en-Y gastric bypass. Arq Bras Cir Dig 2021; 34: e1614
5 Hernández Mondragón OV, Zamarripa Mottú RA, García Contreras LF. et al. Clinical feasibility of a new antireflux ablation therapy on gastroesophageal reflux disease (with video). Gastrointest Endosc 2020; 92: 1190-1201